Trial · NCT06529406
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | New T2 lesions count | 36 months | Number of new T2 lesions on MRI scans. |
| Primary | Serious infections | 36 months | Infections requiring hospitalization, intravenous antibiotic use, or prolonged antibiotic use for treatment of an infection for at least 30 days. |
| Secondary | Relapses | 36 months | Protocol and/or suspected relapses |
| Secondary | IgG and IgM levels | 36 months | IgG and IgM levels |
| Secondary | Infections | 36 months | All infections including opportunistic infections. |
| Secondary | No Evidence of Disease Activity (NEDA-3) | 36 months | Not meeting any of the following criteria: 1. Evidence of Relapse activity - collected every 3 months via phone calls/clinic visits. 2. MRI disease activity - presence of new T2 lesions from MRI scans conducted at any timepoint. 3. 6 months Confirmed Disability progression (CDP6): measured by the EDSS assessed at baseline and every 6 months. CDP6 is defined as an increase in Expanded Disability Status Scale (EDSS) score of ≥1.5 if baseline EDSS was 0; or ≥1.0 points if baseline EDSS was ≥0.5-≤5.5; or by ≥0.5 points if baseline EDSS ≥6, sustained over two consecutive visits. |
| Secondary | Neurofilament light (NfL) and Glial Fibrillary Acid Protein (GFAP) | 36 months | Neurofilament light (NfL) and Glial Fibrillary Acid Protein (GFAP) |
| Secondary | Brain parenchymal and thalamic volume loss | 36 months | Brain parenchymal and thalamic volume loss |
| Secondary | Adverse Events | 36 months | Adverse Events |
| Other | Symbol Digital Modalities Test | 36 months | A 4 points or 10% change in cognition |
| Other | 9-hole peg test | 36 months | A 20% change in hand function |
| Other | 25-foot walk speed | 36 months | A 20% change in walking speed |
| Other | Multiple Sclerosis Functional Composite (MSFC) | 36 months | A change in any of the above three criteria |
| Other | PRO outcomes | 36 months | Include treatment satisfaction (TSQM), MS fatigue scale (Modified Fatigue Impact Scale \[MFIS\]), or quality of life (MSIS-29). A minimum of 5% change. |
| Other | Changes in employment | 36 months. | Changes in employment and full employment status. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06529406/registered